Do-Tzach

Do-Tzach is an Israeli biotechnology company focused on developing repurposed drug combinations for the treatment of viral and inflammatory diseases. The company's lead candidate, DTZ-001, is an oral formulation combining bromocriptine and diclofenac, designed to modulate the immune response and prevent the "cytokine storm" associated with severe COVID-19. Do-Tzach has completed Phase 2a clinical trials in Israel, demonstrating promising results in reducing hospitalization time and improving recovery rates for COVID-19 patients. By utilizing existing FDA-approved drugs, the company aims to provide a safe, rapid, and cost-effective therapeutic solution for pandemic-related and endemic respiratory threats. Do-Tzach continues to explore the application of its therapeutic approach to broader viral infections and systemic inflammatory conditions.